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Abstract
It has been established that c-Jun N-terminal kinase 1 (JNK1) is essential to the pathogenesis of insulin resistance and type 2
diabetes. Although JNK influences inflammatory signaling pathways, it remains unclear whether its activity in macrophages
contributes to adipose tissue inflammation and ultimately to the regulation of systemic metabolism. To address whether
the action of this critical inflammatory kinase in bone marrow-derived elements regulates inflammatory responses in obesity
and is sufficient and necessary for the deterioration of insulin sensitivity, we performed bone marrow transplantation
studies with wild type and JNK1-deficient mice. These studies illustrated that JNK1-deficiency in the bone marrow-derived
elements (BMDE) was insufficient to impact macrophage infiltration or insulin sensitivity despite modest changes in the
inflammatory profile of adipose tissue. Only when the parenchymal elements lacked JNK1 could we demonstrate a
significant increase in systemic insulin sensitivity. These data indicate that while the JNK1 activity in BMDE is involved in
metabolic regulation and adipose milieu, it is epistatic to JNK1 activity in the parenchymal tissue for regulation of metabolic
homeostasis.
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Introduction
Over the last decade discoveries in the metabolism field, starting
with the association of increased tumor necrosis factor alpha
(TNF-a) and other inflammatory cytokines in obesity, have
demonstrated the strong inflammatory underpinnings of obesity
and associated metabolic diseases [1–3]. Obesity leads to elevated
production of pro-inflammatory molecules such as TNF-a, IL-6,
IL-1b, and MCP-1 in experimental murine models and in
humans, notably in adipose tissue [4–7]. Furthermore, migration
of inflammatory cells to obese adipose tissue, particularly at later
stages of the disease, may contribute to and possibly propagate
inflammatory responses [8,9]. Alterations in lipids and lipid
mediators represent another potential component of both
inflammatory responses and insulin resistance in obesity [10–14].
Recently, several mechanistic models have been proposed to
explain the emergence of inflammatory and stress responses in
obesity and type 2 diabetes, including organelle dysfunction
influencing mitochondria and endoplasmic reticulum (ER) and
associated stress signaling pathways [7,15,16]. While it has yet to
be determined whether inflammatory and stress signaling
pathways are proximal or distal to organelle dysfunction or
triggered by peptide or lipid mediators, it is evident that many of
these harmful responses have common targets in regulating insulin
receptor signaling. One such target is insulin receptor substrate 1
(IRS-1) serine phosphorylation which is mediated by inflammatory
kinases such as c-Jun N-terminal kinase (JNK) and IkB kinase beta
(IKKb) and consequently modulates insulin action [17–19].
Pharmacological inhibition or genetic ablation of either JNK1 or
IKKb is effective in the treatment of experimental insulin
resistance and diabetes [20–23].
JNK, a member of the mitogen-activated protein (MAP) kinase
family, is activated by a wide variety of stimuli, including cytokines
and environmental stress[24]. Previous work by our laboratory
and others has shown that JNK1 is necessary for TNF-a induced
serine phosphorylation of IRS-1 and insulin resistance in cells and
animals [21,23,25]. Whole body genetic deficiency of JNK1, but
not JNK2, results in marked protection against insulin resistance
and hepatosteosis induced by obesity [23]. JNK activity has also
been linked to adverse metabolic outcomes in several critical
cellular models and tissues. For example, in b-cells of the islet of
Langerhans, activation of JNK is involved in the reduction of
insulin gene expression and suppression of the JNK pathway
protects b-cells against oxidative stress [26]. Additionally,
inhibition of JNK activity in liver cells using either dominant
negative JNK1 or shRNA against JNK1 lowers circulating glucose
and insulin levels and increases insulin sensitivity in obese models
[27,28]. In contrast, JNK1 activity has little effect on muscle
glycogen levels or the protein levels of key molecules involved in
glucose metabolism, suggesting that enhanced skeletal muscle
glucose metabolism may not underlie the direct beneficial effects of
JNK1-deficiency in mice [29,30]. The combined results of these
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metabolic disease depending upon tissue and cell type examined.
Adipose tissue inflammation is a critical pathophysiological
mechanism underlying obesity-induced metabolic changes [7] and
immune cells infiltrate adipose tissue during the late stages of
obesity. It remains to be determined, however, whether contribu-
tions of bone marrow-derived cells or those of the parenchymal
elements are primarily responsible for triggering the inflammatory
changes and dictate the detrimental metabolic outcomes of
obesity. In the ApoE-deficient model of atherosclerosis, JNK1
activity in the bone marrow-derived cells had no measured effect
on metabolic parameters [31]. However, due to the limitations of
this model to evaluate insulin action, we examined the role of
JNK1 activity in bone marrow-derived elements in development of
high fat diet-induced insulin resistance in the C57BL/6 genetic
background. Since JNK1 action has been shown to lie at the
interface of obesity and inflammation and the results of several
studies indicate that macrophage activity may contribute to insulin
resistance in diet-induced obesity, we performed bone marrow
transplant experiments to test whether myeloid JNK1 regulates the
development of insulin resistance. Specifically, we transplanted
JNK1-deficient bone marrow into wild type (WT) mice and
examined the metabolic impact in the resulting chimeras. We also
performed the inverse transplantation experiments to determine
the effects of JNK1 activity in the parenchymal tissues on systemic
metabolic homeostasis in mice. We conclude that parenchymal
JNK1 plays a predominant role in mediating insulin sensitivity in
non-immune cells.
Results
Regulation of lipid-induced inflammatory responses in
macrophages by JNK1 in vitro
To address the impact of JNK1 activity on the inflammatory
capacity of myeloid cells, we examined free fatty acid-induced
inflammatory cytokine expression in WT and JNK1-deficient
macrophages. For these experiments, we isolated primary
peritoneal macrophages from age- and sex-matched Jnk1
+/+ and
Jnk1
2/2 mice and exposed these cells to the saturated fatty acid
palmitate. In these cells, we examined the expression levels of IL-6,
IL-1b, and TNF-a mRNAs (Fig. 1). Expression levels of these
cytokines were significantly decreased in Jnk1
2/2 peritoneal
macrophages compared to WT controls (Fig. 1). These results
demonstrate that, under the experimental conditions employed,
JNK1-deficiency exhibits a significant impact on the inflammatory
output of macrophages upon exposure to palmitate (Fig. 1). These
results encouraged us to examine the impact of bone marrow-
derived JNK1-deficiency in vivo.
Generation of JNK1-deficient radiation chimeras
Bone marrow transplantation experiments in genetically
modified murine models have been a powerful tool to examine
whether immune cells contribute to a given pathology in vivo. We
initially performed optimization protocols for bone marrow
transplantation procedures resulting in efficient reconstitution
using B6.SJL Ptprc
aPep3
b/BoyJ (CD45.1
+) and C57BL/6
(CD45.2
+) mice. We carried out bone marrow transplantation
experiments with three different doses of irradiation then
determined the ratios of engraftment in blood cells using FACS
analysis for CD45.1 and CD45.2 cell surface markers. We also
examined body weight changes in the post-transplantation period.
These experiments demonstrated that in mice exposed to 10 or 12
Gy of irradiation, the blood cells exhibited more than 98%
reconstitution whereas 9 Gy exposure reduced engraftment to
52% (Fig. 2). Mice receiving the lower doses of irradiation gained
more weight during the following weeks. Since 10 or 12 Gy
irradiation resulted in similar engraftment ratios, we proceeded
with the lower dose to reduce the stress and capitalize on the
slightly improved recovery and weight gain patterns following
transplantation (Fig. 2).
Once an effective bone marrow transplantation procedure was
established, this protocol was applied to JNK1-deficient and wild
type mice on the C57BL/6 genetic background. To examine the
contribution of JNK1 activity in bone marrow-derived cells to
insulin sensitivity and metabolic regulation, we created WT mice
chimeric for myeloid JNK1 expression using bone marrow from
WT or JNK1-deficient (Jnk1
2/2) donor mice to transplant into
WT recipients. In this study, 8-week old C57BL/6 male mice were
lethally radiated (10 Gy) and transplanted with either Jnk1
2/2
(Jnk1
2/2RWT experimental group, n=7) or WT (WTRWT
control group, n=6) bone marrow. As JNK1-deficiency does not
yield a significant metabolic phenotype on standard diet, mice
were fed a high fat diet starting from 8 weeks up to 35 weeks of
age [23]. We determined engraftment by genotyping the blood
Figure 1. Inflammatory responses in JNK1-deficient macrophages. Primary macrophages isolated from wild type (WT) or JNK1-deficient
(Jnk1
2/2) mice were stimulated with 250 mM palmitate (PA) for 24 hours. Expression levels of IL-1b, IL-6 and TNF-a mRNAs were determined by real
time quantitative RT-PCR and normalized to 18S rRNA. Data are normalized to bovine serum albumin (BSA) treated WT macrophages and expressed
as mean 6 s.e.m. Statistical significance is determined by Student’s t test, * p,0.05 and *** p,0.005.
doi:10.1371/journal.pone.0003151.g001
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genotype and quantified percentage engraftment based on allele
distribution (genomic tail DNA served as control, Fig. 3A,B). We
also determined the engraftment of the transplanted bone marrow-
derived cells in several key recipient sites including liver as well as
epididymal and subcutaneous adipose tissues (Fig. 3C). In all
tissues examined, the presence of the donor allele in the recipient
tissues confirmed the success of transplantation in each experi-
mental animal used in the study. To determine the impact of
JNK1 activity in the parenchymal components, we transplanted
bone marrow from WT or Jnk1
2/2 donor mice into JNK1-
deficient recipients (WTRJnk1
2/2, n=6 and Jnk1
2/2RJnk1
2/2,
n=6) using the same experimental protocol and quantified
engraftment in blood cells (genomic tail DNA served as a control,
Fig. 3D,E). We also determined the presence of transplanted bone
marrow-derived cells in liver as well as epididymal and
subcutaneous adipose tissues and confirmed the presence of the
donor allele in the recipient tissues and success of transplantation
in each experimental animal used in the study (Fig. 3F).
We did not observe any difference in the total body weight of
animals in either chimeric recipient groups, Jnk1
2/2RWT and
WTRWT or WTRJnk1
2/2 and Jnk1
2/2RJnk1
2/2 groups
(Fig. 3G,H). Maximum body weight was approximately 40g, which
is lower than what one would achieve in non-transplanted mice that
are placed on high fat diet immediately following weaning and
without irradiation. These results are consistent with many other
reports utilizing transplantation or late placement on diet [32–34].
We repeated these experiments in three independent groups and
each time the results were essentially identical with no change in
body weight between groups (data not shown). In the WT recipient
Figure 2. Effects of irradiation dosage on engraftment and body weight. Mice that differ in CD45 cell surface markers were irradiated with 9,
10, and 12 Gy and transplanted with bone marrow (1610
6 bone marrow cells) and the rate of chimerism in blood cells were determined by sorting
with the specific antibodies for CD45.1 and CD45.2. In an additional control experiment, FACS analysis was performed without BMT using blood cells
from C57BL/6J (CD45.2+) and B6.SJL Ptprc
aPep3
b/BoyJ (CD45.1+) mice (A). FACS analysis using blood cells from CD45.1RCD45.2 BMT in mice that
were irradiated with 9 Gy (B), 10 Gy (C), or 12 Gy (D). Body weight change in the three groups of mice (irradiated with 9, 10, and 12 Gy) following BMT
on a regular diet (E). Percentage of reconstitution was calculated and displayed in each graph.
doi:10.1371/journal.pone.0003151.g002
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difference in body weight between the groups and average body
weight reached was under 40g. The liver and epididymal fat pad
weight was similar between the animals, while percentage of
subcutaneous depot was modestly reduced in Jnk1
2/2RJnk1
2/2
compared to WTRJnk1
2/2 (2.4160.49 and 4.8161.14, respec-
tively). These experiments demonstrated that under the experi-
mentalprotocolemployedinourstudy,noneofthechimericmodels
exhibited a weight regulation phenotype. This lack of difference in
body weight allowed a unique advantage to evaluate the impact of
bone marrow or parenchymal JNK1-deficiency on systemic insulin
sensitivity without the potential confounding effects of weight
regulation due to JNK-deficiency.
Metabolic regulation in JNK1-deficient radiation chimeras
To evaluate the metabolic status of all chimeras, we determined
plasma triglyceride, insulin and glucose levels, and serum adipokines
in all animals maintained on high-fat diet. As observed in JNK1-
deficient mice, serum lipid levels did not differ in any of the chimeric
groups with bone marrow (Fig. 4A) or parenchymal (Fig. 4B) JNK1-
deficiency. We also determined plasma insulin and glucose levels in
mice that were kept on a high-fat diet for 16 weeks. Among the WT
recipients,wedidnotobserveanydifferenceinseruminsulin(Fig.4C)
or glucose (Fig. 4D) levels between Jnk1
2/2RWT and WTRWT
m i c e .I nb o t hg r o u p s ,s e r u mi n s u l i na n dg l u c o s el e v e l si n c r e a s e d
compared to the measurement made at the outset of the study,
showing the effect of the dietary intervention in promoting insulin
resistance. Interestingly, the serum profiles were significantly different
in the Jnk1
2/2recipientchimeras. Inthisgroup, WTRJnk1
2/2mice
developed relative hyperglycemia and had increased fasting plasma
insulin levels compared to Jnk1
2/2RJnk1
2/2 (Fig. 4E,F). Plasma
insulin and blood glucose levels in WTRJnk1
2/2 chimeras were at
intermediate levels between Jnk1
2/2RJnk1
2/2 and Jnk1
2/2RWT
or WTRWT groups (Fig. 4C–F). These observations indicated
possible protection against insulin resistance when the parenchymal
cells lack JNK1 and the potential dominance of this effect on systemic
metabolic regulation. Furthermore, we examined serum adipokine
levels between the four chimeric groups to determine whether
myeloid JNK1 affects adipokines secretion. Analysis of serum resistin,
leptin, and adiponectin levels at 8 (data not shown) and 24 weeks of
age (Fig. 4G–I) revealed no significant regulation of serum adipokines
by either myeloid or parenchymal JNK1-deficiemcy, possibly due to
irradiation’s effect on weightregulation as previously discussed. These
results demonstrate a modest impact of the WT bone marrow-
derived cells on the protective phenotype of parenchymal JNK1-
deficiencyas judged by steady state insulin and glucosemeasurements
indicating the role of bone marrow-derived cells in glucose
metabolism.
Figure 3. Generation of JNK1-deficient radiation chimeras using bone marrow transplantation. The extent of engraftment of the
transplanted cells in WT recipients after bone marrow transplantation was determined using genomic DNA isolated from whole blood and quantified
with PCR-based allele distribution (A and B). Genomic DNA harvested from tail confirmed the presence of only the recipient genotype (A) while
genomic DNA from liver, subcutaneous fat, and epididymal fat tissues (C) confirmed engraftment of donor (Jnk1-deficient) cells in WT recipients.
Genomic DNA isolated from blood was quantified as in panel A except in the Jnk1
2/2 recipient groups (D and E). Genomic DNA isolated from the
liver, subcutaneous fat, and epididymal fat tissues (F) of Jnk1
2/2 recipients confirmed the genotype and engraftment, respectively. At 8 weeks of age,
all WT (G) and Jnk1
2/2 (H) recipient chimeras transplanted with WT or Jnk1
2/2 bone marrow cells were placed on high fat diet and body weights
were monitored for the duration of experiments.
doi:10.1371/journal.pone.0003151.g003
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sensitivity, we performed insulin and glucose tolerance tests in all
four groups of animals (Fig. 5). In both tests, results generated from
mice with intact JNK1 in the parenchymal cells (Jnk1
2/2RWT
and WTRWT) were the same regardless of their bone marrow-
derived JNK1 activity (Fig. 5A and B), demonstrating that when
the JNK1 activity is present in the parenchyma, JNK-deficiency in
the bone marrow-derived cells is not sufficient to influence insulin
sensitivity. Mice with JNK1-deficient bone marrow activity exhibit
enhanced glucose tolerance (Fig. 5C) and insulin sensitivity
(Fig. 5D) only when the parenchymal cells are also deficient in
JNK1. Taken together, these results indicate that while the
principal impact of JNK-deficiency on systemic insulin sensitivity is
driven by the parenchymal elements, bone marrow-derived cells
also contribute to its total impact, although to a lesser extent.
Adipose tissue inflammation in JNK1-deficient chimeras
We next examined histological sections from adipose tissues
isolated from all groups of animals to determine the effect of
myeloid JNK1 on macrophage infiltration and adipocyte mor-
phology. In epididymal adipose depots of WT recipient groups,
there was a modest increase in mononuclear infiltration compared
to Jnk1
2/2 recipients regardless of the donor bone marrow type
(Fig. 6A). Analysis of F4/80, a macrophage specific marker,
Figure 4. Steady state plasma lipid, glucose, insulin, and serum adipokine concentrations in JNK1-deficient chimeras. Serum samples
were collected after a 6 hr food withdrawal from mice from the indicated chimeric groups at 8 and 24 weeks of age. Triglycerides were measured
from WT (A) and Jnk1
2/2 recipients (B) transplanted with either WT or Jnk1
2/2 bone marrow. Serum insulin (C) and blood glucose (D) levels were
measured in the WT recipient groups. Serum insulin (E) and blood glucose (F) levels measured in the Jnk1
2/2 recipient groups. Serum resistin (G),
leptin (H), and adiponectin (I) levels measured in the WT and Jnk1
2/2 recipient groups at 24 weeks of age. Data are expressed as mean 6 s.e.m.
Asterisk indicates statistical significance (p,0.05) in Student’s t test.
doi:10.1371/journal.pone.0003151.g004
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2/2
recipients (0.78 vs. 0.28 AU), but the expression level was not
significantly different within the same recipient groups (Fig. 6B).
Similar results were also obtained after immunohistochemical
analysis of F4/80 protein staining and quantification of crown-like
structuresinadipose tissue (Fig. 6C,D). Theseexperimentsindicated
that in either recipient group, the genotype of the donor bone
marrow did not influence the degree of mononuclear cell infiltration
in chimeric mice but parenchymal Jnk1
2/2 mice had reduced signs
of inflammation compared to WT recipients, regardlessof the donor
genotype.
Although mononuclear cell infiltration was not affected, we
found that JNK1 activity in the bone marrow-derived cells did
alter the inflammatory milieu of the adipose tissue. Interestingly,
Jnk1
2/2RWT animals had significantly lower IL-6 and IL-1b
expression in adipose tissue (Fig. 6E). TNF-a expression trended
toward lower, but did not reach statistical significance (p.0.07).
However, MCP-1, MIF-1, and CD68 expression were not
significantly different in the epididymal adipose tissue between
Jnk1
2/2RWT and WTRWT mice. Similarly, IL-6 levels in
WTRJnk1
2/2 chimeric mice were higher than those detected in
the Jnk1
2/2RJnk1
2/2 group (Fig. 6F). In this group the
difference in IL-1b levels did not reach statistical significance,
and expression of other adipokines, MCP-1, MIF-1, TNF-a and
CD68, were not altered between the groups (Fig. 6F). These results
demonstrated that while the inflammatory status of the adipose
tissue could be moderately altered by bone marrow-derived JNK1
deficiency, this is insufficient to yield a detectable benefit on
systemic insulin sensitivity when the parenchymal cells are intact at
the JNK1 locus, under the experimental conditions and assays
utilized in this study.
We also determined JNK1 activity in the adipose tissue of
chimeric mice to assess the contribution of parenchyma- and bone
marrow-derived elements to obesity related activation of this
pathway. In the WT recipient group, there was robust JNK
activation in the adipose tissue (Fig. 7A). Since bone marrow-
derived cells are a small percentage of total cell population in the
adipose tissue, it is not surprising that there was no significant
difference in total JNK activity, calculated by the ratio of
phosphorylated c-Jun to JNK1 protein, between Jnk1
2/2RWT
and WTRWT chimeras. The level of JNK activation in the
Jnk1
2/2 recipient group was significantly lower than the WT
recipient group. This result indicates that the main source of
obesity-induced JNK activity in adipose tissue is the parenchymal
elements such as adipocytes. Nevertheless, in parenchymal JNK1-
deficiency, we were able to detect a modest JNK activity in the
WTRJnk1
2/2 but not in the Jnk1
2/2RJnk1
2/2 chimeras,
confirming the WT cell deposition in the adipose tissue and the
potential impact of bone marrow transplantation. In these mice,
we also examined insulin-stimulated tyrosine phosphorylation of
the insulin receptor to determine the status of local insulin
responsiveness in adipose tissue in intact mice following insulin
administration. Insulin-stimulated tyrosine 1162/1163 phosphor-
ylation of insulin receptor beta subunit was modestly decreased in
the adipose tissue of WTRJnk1
2/2 mice compared with that of
Jnk1
2/2RJnk1
2/2 controls (Fig. 7B). These results demonstrate
Figure 5. Glucose tolerance and insulin sensitivity in JNK1-deficient chimeras. Glucose (GTT) and insulin (ITT) tolerance tests were
performed on mice at age 22 and 26 weeks, respectively. GTT (A) and ITT (B) experiments after intraperitoneal injection of glucose or insulin in WT
recipient mice transplanted with WT or Jnk1
2/2 bone marrow. GTT (C) and ITT (D) in Jnk1
2/2 recipient mice transplanted with WT or Jnk1
2/2 bone
marrow. All data are presented as mean 6 s.e.m. Statistical analysis was performed by Student’s t test. *p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0003151.g005
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PLoS ONE | www.plosone.org 6 September 2008 | Volume 3 | Issue 9 | e3151Figure 6. Adipose tissue inflammation in JNK1-deficient chimeras. Photomicrographs of adipose tissue sections were generated after
staining with hematoxylin/eosin or anti-F4/80 and hematoxylin. Epididymal adipose tissue sections were prepared from all groups of mice, Jnk1
2/2
RWT, WTRWT, WTRJnk1
2/2 and Jnk1
2/2RJnk1
2/2, on high-fat diet for 27 weeks (A). In the same adipose tissue samples, total RNA was extracted
and F4/80 mRNA expression level was quantified as an indicator of macrophage infiltration (B). Adipose tissue sections were also stained with anti-F4/
Parenchymal JNK and Diabetes
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altered inflammatory profile and impaired insulin sensitivity in the
adipose tissues of Jnk1
2/2 mice, this effect is rather modest in
magnitude. These results again demonstrated that parenchymal
JNK-deficiency is the dominant determinant in the role of obesity-
induced metabolic complications.
Effects of JNK1 activity on liver and subcutaneous
adipose tissue
Since myeloid JNK1 deficiency did not protect against
macrophage recruitment in epididymal adipose tissue, we
examined histological sections of liver isolated from all groups to
determine the effect of myeloid JNK1 on hepatic triglyceride
content. Comparison of liver sections revealed that there was a
strong association of lipid accumulation with recipient group
(Fig. 8A), similar to the observation of macrophage recruitment.
Indeed, in the WT recipient groups there was an increase in
hepatic triglyceride content compared to Jnk1
2/2 recipients
groups (68.667.7 mg/g vs. 5.9861.06 mg/g, respectively,
p,0.0001), although there was no significant difference within
the chimeric groups (Fig. 8B).
We further investigated the liver phenotype to determine
whether bone marrow derived elements affected the inflammatory
state of the liver. In the WT recipient group, we were unable to
detect any alterations in IL-1b, IL-6, TNF-a, and F4/80
expression (Fig. 8C) between the donor types. Interestingly,
WTRJnk1
2/2 animals had statistically significant increase in
hepatic TNF-a and F4/80 expression (Fig. 8D). However, analysis
of IRS-1, IR, and Akt phosphorylation did not show alterations in
the insulin signaling pathway between the two groups (data not
shown). We also examined the inflammatory milieu of the
subcutaneous adipose depot, which is often different from that of
the epididymal adipose tissue when animals are placed on high fat
diet. In the WT recipients, JNK1-deficiency in the BMDE resulted
in lower TNF-a expression (Fig. 8E). Other cytokines examined
were unchanged. In contrast, the Jnk1
2/2 recipients had no
statistically significant alterations in cytokine expression in the
subcutaneous tissue (Fig. 8F). In all groups and tissues tested,
MCP-1 and CD68 expression levels were unchanged within the
groups (data not shown). These results suggest that myeloid
JNK1’s regulation of cytokine expression is tissue specific and that
parenchymal JNK1 activity may influence myeloid JNK1’s effects.
Discussion
Previous studies have demonstrated that whole body JNK1-
deficiency results in protection from genetic and diet-induced
obesity and insulin resistance [23]. Recently, the critical role of
liver JNK activity was also demonstrated by linking liver-restricted
activation or suppression of JNK1 to strong systemic metabolic
regulation, indicating that this site is critical in the role of JNK in
insulin resistance [27]. A similar observation was made for another
inflammatory kinase, IKKb, where its liver-restricted activation or
suppression was sufficient to alter systemic insulin action [35].
Genetic interference with regulators of inflammatory pathways,
such as IKKb and PPARc, in myeloid derived cells has also been
demonstrated to confer partial protection from insulin-resistance
[32,35,36]. Our studies show that JNK1 activity in myeloid cells
influences the cellular milieu of the adipose tissue and liver as well.
Interestingly, however, the effect of myeloid JNK1 on the
inflammatory cytokine expression is dependent on the tissue type
examined. When JNK1 is present in the parenchyma, JNK1-
deficieny in the bone marrow-derived cells does not confer
protection against diet-induced insulin resistance, despite detect-
able but modest effects on adipose tissue inflammation. We were
80 antibody to detect the protein levels (C) and the number of crown like structures (CLS) were quantified (D). Expression levels of IL-1b, MCP-1, MIF-
1, CD68, TNF-a, and IL-6 mRNAs in the epididymal adipose tissue were quantified to determine the cellular milieu in the WT (E) or Jnk1
2/2 (F)
recipient groups transplanted with WT or Jnk1
2/2 bone marrow. Asterisk indicates statistical significance (p,0.05) in Student’s t test.
doi:10.1371/journal.pone.0003151.g006
Figure 7. Adipose tissue JNK activity in JNK1-deficient chimeras. Total adipose tissue JNK kinase activity (A) and insulin-stimulated insulin
receptor phosphorylation (B) were examined in JNK1-deficient mice transplanted with WT or Jnk1
2/2 bone marrow. Lower graph in panel B shows
the quantification of insulin receptor phosphorylation normalized for insulin receptor protein levels. In the JNK kinase assay, the density of each lane
is also shown numerically. Asterisk indicates statistical significance (p,0.05) in Student’s t test.
doi:10.1371/journal.pone.0003151.g007
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+/+
macrophages on Jnk1
2/2 recipients. These results indicate that
JNK1 activity in myeloid cells is not sufficient to alter systemic
glucose metabolism and that parenchymal JNK activity is the
dominant determinant for metabolic homeostasis.
Furthermore, our results also suggest that conditions that alter the
inflammatory gene expression in bone marrow-derived cells would
not always yield corresponding changes in systemic insulin sensitivity.
In this sense, the metabolic status of the parenchymal targets such as
adipocytes or hepatocytes appears to be the driver of both
inflammatory alterations and their systemic metabolic consequences.
Although similarly identifying a role for JNK1 outside the
parenchyma, a recent work by another group came to somewhat
different conclusions regarding the magnitude of the contributions of
JNK activity in the bone marrow-derived elements on systemic
insulin action, where JNK1-deficiency in the bone marrow was
Figure 8. Hepatic triglyceride accumulation and inflammatory cytokines expression in the liver and subcutaneous adipose tissue.
Photomicrographs of liver sections were generated after staining with hematoxylin/eosin. Liver sections were prepared from all groups of mice,
Jnk1
2/2RWT, WTRWT, WTRJnk1
2/2 and Jnk1
2/2RJnk1
2/2, on high-fat diet for 27 weeks (A). In the same liver samples, triglycerides were
extracted and quantified (B). Additionally, total RNA was extracted and expression levels of IL-1b, IL-6, TNF-a, and F4/80 were quantified to determine
the cellular milieu in the WT (C) or Jnk1
2/2 (D) recipient groups transplanted with WT or Jnk1
2/2 bone marrow. Similarly, mRNA was extracted from
subcutaneous adipose tissue in the WT (E) or Jnk1
2/2 (F) recipient groups and subjected to quantitative-PCR analysis of the IL-1b, IL-6, TNF-a, and F4/
80 expression. Asterisk indicates statistical significance (p,0.05) in Student’s t test.
doi:10.1371/journal.pone.0003151.g008
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In this study, the disease in general appeared to be more advanced
despite a later start of dietary interventions, manifesting in higher
averagebodyweightsandmoreseveredisease.Hence,the differences
in our results can be explained by the differences in bone marrow
transplantation protocols (early vs. late dietary invention and the
timing of the transplantation) and the magnitude of the disease
achieved through high fat diet exposure. It is possible that at later
stages of the disease, massive degeneration of tissue and recruitment
of higher numbers of macrophages could exhibit a larger impact on
general metabolism through the actionof these bone marrow-derived
cells, as reported [37].
In this study, we did not observe any changes in total body weight
between the chimeric groups, whereas without transplantation,
JNK1-deficiencyresults in a modestreductioninadiposityona high
fat diet [23]. This difference in body weight patterns is most likely
due to the irradiation and delayed exposure time to diet which
results in milder weight gain as reported in many previous studies
[34]. In fact, irradiation prevented increased adiposity even in the
ob/ob model of severe genetic obesity, as recently reported by
Ablamunits, et al., but did not interfere with the development of
insulin resistance [33]. This is consistent with our observations
where we did observe the development of insulin resistance with
differences in body weight between groups which allowed
examination of the impact of JNK activity independent of
secondary effects of body weight and adiposity. At this early stage
disease model, the parenchymal cells such as adipocytes and
hepatocytes appear to drive the initial events impacting insulin
sensitivityand glucose metabolism.The ability to modulate systemic
insulin sensitivity through manipulation of JNK1 action in the liver
also supports this inference [27,28]. It would be interesting to
determine whether a similar impact could be generated by
adipocyte-specific alterations in JNK activity in mice.
Nonetheless, our results demonstrate that myeloid JNK1 plays a
role in the regulation of cytokine expression in adipose tissue and
the development of insulin resistance in type 2 diabetes, however,
it does not appear to be the driver of this phenotype at earlier
stages of obesity and insulin resistance, supporting the concept that
metabolic target cells are likely to provide the initial inflammatory
and/or stress signals that result in metabolic deterioration and
their involvement is paramount to metabolic disease.
Materials and Methods
Macrophage studies
Primary macrophages were harvested from Jnk1
+/+ or Jnk1
2/2
mice for analysis of alterations in gene expression as previously
described [13]. Isolated primary monocytes were plated in RPMI
1640 (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum
(Hyclone, Logan, UT), 1% penicillin-streptomycin (Invitrogen) for
24 hr at 10
4 cells/well in 6-well plates. Next day, macrophages
were treated with 0.5% bovine serum albumin (BSA) or 0.5 mM
palmitate in 0.5% BSA in RPMI for 24 hr. All of the procedures
in this study were in accordance with Institutional Animal Care
and Use Committee of Harvard University, Cambridge, MA.
Generation of radiation chimeras, transplantation
protocols, and fluorescence-activated cell sorter (FACS)
analysis
Development and characterization of Jnk1
2/2 mice were
described elsewhere [38]. B6.SJL Ptprc
aPep3
b/BoyJ (CD45.1
+)a n d
C57BL/6 (CD45.2
+) mice were obtained from Jackson Laboratory.
Bone marrow was collected from donor mice (10–12 weeks of age)
by flushing femurs with phosphate buffered saline (PBS). Recipient
mice (8 weeks old) were lethally irradiated (9, 10, or 12 Gy) by a
cesium gamma source. Four hours later, 5–10610
6 bone-marrow
cellsin0.3 mlvolumeweretransplantedbyintravenousinjection,as
described[39]. One-week prior and 2-weeks post-bone marrow
transplantation, 100 mg/L neomycin and 10 mg/L polymyxin B
sulfate (Sigma-Aldrich, St. Louis, MO) were added to the acidified
water. Fluorescence-activated cell sorter (FACS) analysis was
performed using peripheral blood cells collected from recipient
mice 4 weeks after the bone marrow transplantation and staining
with antibodies against the cell-surface markers, PE-CD45.1 and
FITC-CD45.2 (eBioscience, San Diego, CA). Following incubation
with the primary antibodies, FACS lysing solution was added, cells
were centrifuged at 1000 g for 2 min, resuspended in 1 ml
FACSflow fluid and analyzed on a FACSCalibur apparatus using
CellQuest software (all BD Bioscience, San Jose, CA).
Genotyping
Genomic DNA was harvested from whole blood as described
[40] and resuspended in dH20. Percentage of engraftment was
evaluated by the allelic ratios. Genomic DNA from liver,
subcutaneous fat, and epididymal fat was isolated with DNeasy
tissue isolation system (Invitrogen) for use in PCR-based genotyping
of wild type and JNK1-deficient alleles as previously described [38].
Metabolic studies
Male mice were housed in a pathogen-free facility and placed on
a high-fat/high-caloric diet (D12492: 60% kcal% fat; Research
Diets, Brunswick, NJ) ad libitum starting at 8 weeks of age and were
followed for a period of up to 36 weeks. Body-weight measurements
were taken starting at 8 weeks of age. Blood samples were collected
after a 6-h daytime fast at indicated ages. Serum glucose, insulin,
and triglyceride levels were measured as described [2,23]. Serum
levels of resistin (Millipore, Billerica, MA), leptin (Alpco, Salem,
NH), and adiponectin (Alpco, Salem, NH) were measured following
the provided protocol. Glucose and insulin tolerance tests were
performedon consciousmiceaftera 14-h or6-hfast,respectively, as
described [2,12,23], with intraperitoneal administration of glucose
(1.5 g/kg, 22 weeks) or human insulin (1 U/kg, 26 weeks; Lilly
Research Laboratories, Indianapolis). Triglycerides were extracted
from the liver using Bligh and Dryer method [41] and quantified
using Serum Triglyceride Determination Kit (Sigma-Aldrich).
Tissues and gene expression
Total RNA was isolated from epididymal adipose tissue,
subcutaneous adipose tissue, liver, or primary macrophages using
TRIzol reagent and protocol (Invitrogen). The reverse-transcrip-
tion reaction was carried out with the high capacity cDNA reverse
transcription system (Applied Biosystems, Foster City, CA). Real-
time quantitative PCR analysis was performed in a 25-ml final
volume using SYBR green PCR master mix (Applied Biosystems).
The thermal cycling program was: 10 min at 95uC, 40 cycles, 15 s
at 95uC, 30 s at 58uC, and 30 s extension at 72uC. PCR products
were confirmed by melting curve analysis. Quantifications were
normalized to the 18S rRNA level in each reaction. Primer
sequences were as reported previously [12] except MIF with
forward GCCAGAGGGGTTTCTGTCG, and reverse
GTTCGTGCCGCTAAAAGTCA sequences. JNK kinase assays
and insulin receptor phosphorylation experiments were performed
as previously described [12].
Histological analysis
Following sacrifice, a portion of the epididymal adipose tissue
and liver were placed in 10% formalin for 24 hours. Tissue
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prepared from each sample. Samples were deparaffinized, washed
three times and then stained with either H&E and mounted or
incubated with anti-F4/80 and washed. After PBS washes, sections
were incubated with Vectastain ABC-AP Rat IgG Kitand
visualized with ImmPACT DAB Substrate Kit (all Vector
Laboratories, Southfield, MI). Sections were viewed under a
microscope at610 and640 magnification and photomicrographs
were generated with an Olympus CKX41 camera to capture the
presence of macrophages in the epididymal adipose tissue. Data
are reported as number of total adipocytes surrounded by F4/80+
cells per 1000 adipocytes. Samples from at least 5 mice per
genotype were incorporated into the analysis.
Statistical Analyses
Experimental results were shown as the mean 6 s.e.m.
Differences between two sets of data were compared by Student’s
t test. All statistical tests with p,0.05 were considered significant.
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